Introduction
Tumour necrosis factor homologues (TNFs) are involved in various biological responses, such as the regulation of infection, inflammation, autoimmune diseases and tissue homeostasis (Smith et al., 1994; Gravestein and Borst, 1998) . They interact with their corresponding TNF-homologue receptors (TNF-Rs), as membrane-bound proteins in zones of cell-to-cell contact or as far-acting soluble ligands (Smith et al., 1994) . The recently described TNF-homologue, APRIL (a proliferation-inducing ligand) (Hahne et al., 1998) , which is also known as TNF-related death ligand (TRDL1-a) (Kelly et al., 2000) and TNFSF13a, binds B-cell maturation (BCMA) (Laˆabi et al., 1992 (Laˆabi et al., , 1994 Madry et al., 1998) , transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (Shu et al., 1999; Gross et al., 2000; Xia et al., 2000) and a hypothetical but as yet uncharacterized third receptor (APRIL-R) (Rennert et al., 2000) . B-cell activating factor belonging to the TNF family (BAFF) (Schneider et al., 1999) , another TNF-homologue, also binds BCMA , TACI (Marsters et al., 2000; Wu et al., 2000; Yu et al., 2000) , in addition to its own specific receptor, BAFF-R (Thompson et al., 2001) . APRIL is produced in small amounts in peripheral blood lymphocytes (PBLs) and normal tissue but is produced in much larger quantities in malignant tumours, in which it stimulates the growth of malignant cells (Hahne et al., 1998) . APRIL, which is processed by furin convertase within the cell before its secretion, is detected only in soluble form (Lo´pez-Fraga et al., 2001) . Roth et al. (2001) reported APRIL to be present in some malignant glioblastoma cell lines, but with no stimulatory effect on cell growth. In this study, we found that APRIL was abnormally produced in eight human malignant glioblastoma cell lines as this protein was not detected in normal human counterpart cells. We showed that the addition of recombinant APRIL increased the proliferation of the cell lines tested and of normal human adult astrocytes. Addition of the recombinant molecule BCMA-Fc, which blocks secreted APRIL, decreased the proliferation rate of most of the cell lines tested. We also identified a putative specific APRILbinding receptor on malignant glioblastoma cells and their normal counterparts. These data suggest an autocrine loop for APRIL and its specific receptor, promoting the proliferation of glioblastoma cells.
Results

Presence of APRIL, BAFF, TACI, BAFF-R and BCMA transcripts in malignant glioblastoma cell lines
We carried out Northern blotting to test for the presence of APRIL, BAFF, BAFF-R, BCMA and TACI transcripts. We loaded 10 mg of total RNA in each lane, extracted from eight malignant glioblastoma cell lines (CB193, SF126, SKMG12, SNB19, T98G, U118MG, U373MG, U399MG) and the colon carcinoma HT29 cell line. In the conditions used, we detected no APRIL, BAFF, BAFF-R, BCMA or TACI transcripts with the appropriate cDNA probes (data not shown). RT-PCR was then performed to detect small amounts of transcripts of the APRIL, BCMA, BAFF, BAFF-R and TACI genes in the eight glioblastoma cell lines studied. The colon carcinoma HT29 cell line and normal human embryonic astrocytes (considered to be the normal counterpart of the glioblastoma cells, obtained as described in Materials and methods) were also included in the study. BAFF transcripts were not detected in any of the samples used (Table 1) . Similarly, we obtained no evidence for the presence of the BAFF-R transcript, except in the SKMG12 glioblastoma cell line. APRIL and BCMA transcripts were present in all the cell lines used. The TACI transcript was present in all cell lines except the CB193 glioblastoma cell line. Normal embryonic astrocytes did not contain APRIL, BAFF, BCMA or TACI transcripts. Amplification of the b-actin gene from equal quantities of RNA, with specific primers, showed that b-actin transcript levels were similar in all samples tested (data not shown). Thus, abnormal transcription of the BCMA, TACI and APRIL genes occurred in all the glioblastoma cell lines tested except for CB193, in which the TACI transcript was not detected.
APRIL genomic region does not seem to be modified in the glioblastoma cell lines
We investigated whether the abnormal APRIL production by glioblastoma cell lines was due to modification of the APRIL gene region, by carrying out Southern blot analysis with DNA from these cell lines and the following restriction enzymes: HindIII, BamHI and EcoRI. The resulting restriction map of the region of the genome including the APRIL gene is shown Figure 1 . A specific APRIL cDNA probe showed that only normal-size fragments of DNA (8.2 kb for HindIII, 16.6 kb for BamHI and two bands of 3.2 and 3.9 kb for EcoRI) (data not shown) were present, excluding the possibility of a recombination event within 4 kb 5 0 and 8 kb 3 0 of the APRIL gene. Thus, the abnormal production of APRIL by the glioblastoma cell lines is not due to genomic modifications (chromosomal translocation, deletion or insertion) in the proximity of the APRIL gene.
There are specific APRIL receptors on the surface of glioblastoma cell lines, nerve progenitors, embryonic and adult astrocytes
We investigated the binding of the BAFF and APRIL ligands on the surface of glioblastoma and colon carcinoma HT29 cell lines, normal human nerve progenitors, embryonic and adult astrocytes (Figure 2 , (a) for APRIL and (b) for BAFF). BAFF did not bind to the cell surface in most of the lines used. Slight binding was observed on the cells of the SKMG12, SF126 and SNB19 glioblastoma cell lines, suggesting that the BCMA and TACI molecules (which bind both BAFF and APRIL with high affinity) were absent from the surface of these cell lines. In contrast, all these cell 
Rate of proliferation of glioblastoma cell lines and normal human adult astrocytes upon addition of APRIL
We investigated whether the addition of recombinant APRIL increased the proliferation rate of the glioblastoma and HT29 cell lines, by monitoring 3 H-thymidine uptake ( Figure 3 ). The proliferation of the HT29 cell line increased in a dose-dependent manner upon the addition of recombinant APRIL, with a maximal increase of 50% on addition of 25 ng/ml APRIL. Three of the eight glioblastoma cell lines studied showed a large increase in proliferation rate, proportional to the amount of APRIL added. A maximum increase in the rate of proliferation of 85% was observed for U118MG and of 50% for CB193 following the addition of 250 ng/ ml APRIL. For T98G, a maximum increase in the proliferation rate of 90% was attained following the addition of 25 ng/ml APRIL. A fourth cell line, U399MG, displayed a maximum increase in proliferation rate of 20% following the addition of 2.5 ng/ml APRIL. APRIL had no effect on the proliferation of three glioblastoma cell lines: SF126, SNB19, U373MG. Conversely, the addition of APRIL inhibited proliferation in the SKMG12 line. These data suggest that APRIL is involved in cell proliferation in at least four of the eight glioblastoma cell lines tested.
We also investigated the effect of adding recombinant human APRIL to normal human adult astrocytes, using the methyl thiazol tetrazolium bromide (MTT) test, as described in Materials and methods. We found that the rate of cell growth increased significantly following the addition of 100 ng/ml recombinant APRIL (Figure 4) .
Inhibition of the proliferation of glioblastoma cell lines upon addition of soluble BCMA-FC
The presence of APRIL mRNA suggests that APRIL was secreted because the APRIL protein exists only as a soluble form (Lo´pez-Fraga et al., 2001) . The low affinity of the available commercial antibodies precluded adequate quantification of the exact amounts of APRIL in culture supernatants. We therefore assessed the effects of the amount of APRIL produced on the proliferation of glioblastoma cell lines by studying proliferation rates in the presence of various amounts of soluble BCMA-Fc, which is known to block APRIL (Rennert et al., 2000) . Control experiments were performed with equimolar amounts of human IgG. The results are expressed as a ratio of the rate of proliferation of BCMAFc-supplemented cells to that of IgG-supplemented cells. Cell proliferation was inhibited by BCMA-Fc in the T98G, U373MG, U399MG, SNB19 and SF126 cell lines ( Figure 5 ). The addition of these BCMA-Fc or IgG had no effect on the proliferation of the SKMG12 cell line (data not shown). It should be noted that the U373MG, SNB19 and SF126 cell lines, in which the addition of APRIL did not increase proliferation, nonetheless showed a decrease in proliferation rate following the addition of BCMA-Fc. We did not obtain 100% inhibition of proliferation in any of the cell lines used, even if we added 500 ng/ml BCMA-Fc. Indeed, a maximum of only 50% inhibition was observed for the T98G and SNB19 cell lines. These data suggest that the abnormal production of APRIL, even at low levels, may increase the proliferation of glioblastoma cell lines. However, APRIL does not seem to play an exclusive role and there are probably other molecules that also increase proliferation.
Discussion
In this report, we investigated production of the three TNF-homologue receptors BCMA, TACI and BAFF-R, and of their corresponding TNF-homologue ligands, BAFF and APRIL, in eight malignant glioblastoma cell lines. We demonstrated abnormal transcription of the genes encoding the BCMA and TACI receptors and of that encoding the APRIL ligand. We also investigated the abnormal expression of BCMA and TACI on the surface of the glioblastoma cell lines. All but three of the glioblastoma cell lines did not bind BAFF ligand, and the three that did bind this ligand did so only weakly. Thus, no BCMA or TACI is present on the surface of the cell lines to bind BAFF. In contrast, the strong binding of APRIL to the cells of all the lines used suggests the presence of a specific receptor for APRIL on the surface of glioblastoma cell lines, this receptor being different from those previously reported to bind APRIL (BCMA and TACI). The existence of a third receptor for APRIL, on malignant endothelial cell lines, has already been suggested (Rennert et al., 2000) . It should be noted that we also detected this putative receptor on the surface of normal human embryonic, adult astrocytes and on normal human nerve progenitors. All eight glioblastoma cell lines used in this study produced APRIL transcripts. In a previous study (Roth et al., 2001) , APRIL transcripts were detected in five of the 12 glioblastoma cell lines tested. Our panel of glioblastoma cell lines differed from that used in this previous study, with only the U373MG and T98G cell lines common to both studies. Consistent with this previous study, U373MG tested positive for the APRIL transcript. In contrast, we detected APRIL transcripts in the T98G cell line, whereas Roth et al. did not.
We then investigated the effect of soluble recombinant human APRIL on the proliferation of the glioblastoma cell lines. In four of the eight glioblastoma cell lines tested, proliferation rate increased following the addition of APRIL. Three cell lines did not respond to APRIL addition and proliferation was inhibited in the remaining cell line (SKMG12). Propidium iodide staining of SKMG12 cells indicated that apoptosis was not responsible for the inhibition observed (data not shown). Recombinant APRIL also increased proliferation of the HT29 colon carcinoma cell line. The increase in proliferation rate of normal human astrocytes, upon addition of recombinant APRIL, is the first report of an activity of APRIL on normal cells.
Our results differ from those of Roth et al. (2001) , who found that APRIL did not promote glioblastoma cell growth in vitro or in vivo. This discrepancy may be due to the material used: we used defined amounts of pure human recombinant soluble trimeric APRIL, whereas Roth et al. studied the proliferation rate of glioblastoma cell lines transfected with a construct encoding APRIL.
We added soluble BCMA-Fc to cultures to block the secreted APRIL molecules and measured the proliferation rate. We found that proliferation was inhibited in the T98G U399MG, U373MG, SNB19 and SF126 cell lines due to the lack of secreted APRIL caused by the presence of BCMA-Fc. The presence of a specific receptor for APRIL and the secretion of APRIL together suggest the possibility of an autocrine loop in glioblastoma cell lines. Our results also suggest that all glioblastoma cell lines have the specific APRIL receptor, but that these cell lines do not all respond in the same way to APRIL stimulation. Indeed, APRIL may simply be one of many molecules involved in the regulation of tumour cell growth.
Some cytokines, such as stromal cell-derived factor 1 (SDF-1) (Barbero et al., 2003) , epidermal growth factor (EGF) (Held-Feindt et al., 2003) and IL-6 (Goswami et al., 1998) , have been reported to be produced and to increase cell proliferation in glioblastoma cell lines. We investigated whether the addition of APRIL affected the secretion of one of these molecules, IL-6. Our results demonstrate that the increase in proliferation observed following the addition of APRIL was not due to an increase in the amount of secreted IL-6 (data not shown). We found that the addition of APRIL either decreased the amount of secreted IL-6 or had no effect. 
Materials and methods
Reagents
Cell lines and cell cultures
The HT29 cell line is a human colon carcinoma cell line obtained from ATCC. The CHO (dhfrÀ) cell line was purchased from ECACC (Salisbury, UK). The U118MG and CB193 glioblastoma cell lines were kindly provided by Dr Gabriel Gras (CEA, Fontenay aux Roses, France) and Dr Delpech (Centre H Becquerel, CHU de Rouen, France), respectively. The other six glioblastoma cell lines studied were provided by one of us (PH). U399 MG and U373 MG are described as grade IV glioblastoma-astrocytoma. T98G and SNB19 were derived from a human grade IV glioblastoma multiforme tumour. SF126 and SKMG12 are described as grade IV astrocytoma. U118MG is described as grade III astrocytoma-glioblastoma and CB193 as grade III glioblastoma.
Cells were maintained at 371C, under an atmosphere containing 5% CO 2 /95% air in Dulbecco's modified minimal essential medium containing 4.5 g/l glucose (DMEM) (Invitrogen) supplemented with 10% FCS and 2.5 mg/ml plasmocin (Cayla, Toulouse, France).
Human neural cell cultures
Authorisation for experimentation with foetal tissue was obtained from the local ethics committee, in accordance with French guidelines. Foetal brains were obtained from foetuses aborted at 10-13 weeks of gestation. Adherent blood vessels and meninges were removed. The brain tissue was then mechanically dissociated and plated at a density of 5 Â 10 5 cells/ml on 10-cm diameter Petri dishes precoated with DL-polyornithine (40 kDa, 5 mg/ml) as previously described (Chamak and Prochiantz, 1989) . The medium used was DMEM, supplemented with 10% heat-inactivated foetal bovine serum, and antibiotics (penicillin at 100 IU/ml, streptomycin at 100 mg/ml). Cells were cultured for 14-28 days at 371C in a humidified atmosphere containing 5% CO 2 , 95% air, and the medium was changed every 3 days. The cells were subcultured when they reached confluence, every 2-3 weeks, by dilution in fresh medium (1 : 2 or 1 : 3), using trypsin-EDTA. A cell population enriched in astrocytes was generated by subculturing cells at a 1 : 10 dilution. Primary human neuron cultures and subcultures were stained for MAP-5, using a mouse monoclonal antibody (1 : 500), and for GFAP, using a mouse monoclonal antibody (1/200). Under these culture conditions, 70-80% of the cells in neuronal cultures contained MAP-5, the remaining cells being predominantly astrocytes. In astrocyte cultures, about 90% of cells produced GFAP.
Adult human tissue was isolated from the cerebral cortex of patients (mean age, 51.576.2 years) undergoing surgical resections. The patients gave informed consent, in accordance with hospital policy. Immediately after surgery, the tissue was mechanically dissociated and incubated as described elsewhere (Ridet et al., 1999) .
Southern and Northern blots
Southern and Northern blots were performed and the corresponding filters hybridized and subjected to autoradiography as previously described (Davies et al., 1986) .
RT-PCR experiments
The first-strand cDNA was obtained using the Superscript First-Strand Synthesis Kit and the total RNA isolated from cells with Trizol reagent. For PCR amplification experiments, we used Hot-Start Polymerase in a Perkin-Elmer GenAmp 2400 system. The following pairs of primers were used to detect the presence of human transcripts: OAT18/OAT19 for APRIL, OAT28/OAT29 for BAFF, OAT31/OAT32 for BCMA, OAT37/OAT38 for TACI, OAT43/OAT44 for BAFF-R and OAT47/OAT48 for human b-actin. All the amplification experiments began with 15 min at 941C to activate the Hot-Start Polymerase and ended in a 7-min extension step at 721C. The specific cycling conditions for each transcript were: 941C 30 s, 601C 30 s, 721C 23 s Â 30 cycles for APRIL; 941C 1 min, 571C 1 min, 721C 1 min Â 35 cycles for BCMA; 941C 30 s, 551C 30 s, 721C 30 s Â 35 cycles for BAFF; 941C 1 min, 601C 1 min, 721C 2 min Â 35 cycles for TACI; 941C 1 min, 601C 1 min, 721C 1 min Â 35 cycles for BAFF-R and 941C 1 min, 501C 1 min, 721C 1 min Â 30 cycles for bactin. We used 100 ng of cDNA for the detection of b-actin transcripts, 200 ng for BCMA and APRIL, and 400 ng for TACI, BAFF-R and BAFF transcripts.
OAT18
Flow cytometry
Cells (1 Â 10 6 ) were harvested in cold 1 mM EDTA in PBS and incubated for 20 min with FACS buffer (1 mM EDTA in PBS/ 1% BSA/0.2% NaN 3 ) plus 10% human AB serum at 41C. FLAG-APRIL and FLAG-BAFF ligands were added to a concentration of 100 ng/ml. FACS buffer was used as a mock control. The binding of APRIL and BAFF was detected by sequential addition of monoclonal mouse anti-FLAG M2 antibody (8 mg/ml) and PE-conjugated goat F(ab') 2 anti-mouse IgG antibody (1/50). Fluorescence was analysed in a FACScan flow cytometer from BD Biosciences (San Jose, CA, USA).
Proliferation assays
Thymidine assay We used the limiting dilution method to determine cell concentration for each cell line. We then added the appropriate number of cells to 10% FCS in DMEM in 96-well plates, which were then incubated for 24 h at 371C, under an atmosphere containing 5% CO 2 /95% air. On the following day, the cells were transferred to 2% FCS in DMEM supplemented with various amounts of the reagents studied and incubated for a further 48 h. We then added 20 ml [ 3 H]thymidine (1 mCi/ml)/well and incubated the plates for 8 h. Thymidine incorporation was measured in a Beckman betaplate counter.
MTT assay We used a modified version of a previously described method (Hansen et al., 1989) . Astrocytes were added to 10% FCS in DMEM in 96-well plates (1250 and 2500 cells/ well), which were then incubated for 24 h. The medium was then changed to 1% FCS in DMEM, in the presence or absence of human recombinant APRIL (25 or 100 ng/ml). After 72 h, we added 20 ml of a 5 mg/ml MTT solution in PBS to each well. The cells were incubated for 4 h at 371C, under an atmosphere containing 5% CO 2 /95% air. Following this treatment, we added 100 ml of lysis buffer (20% SDS in dimethylformamide (DMF)/H 2 O (1/1) solution, pH 4.7) per well and incubated the cells overnight at 371C. The next day, we measured optical density (O.D.) at 590 nm. Assays were performed in triplicate.
Preparation of soluble BCMA-FC
A hybrid construct encoding the signal peptide sequence of human heavy chain gamma 1 fused to the extracellular part of human BCMA, connected in-phase with the Fc segment of human IgG1, was introduced into the plasmid p7055 (Miloux and Lupker, 1994) . The CHO(dhfrÀ) cells were electroporated with this plasmid and transfected cells were selected on Iscove's medium, supplemented with 10% FCS. The secreted BCMA-Fc protein was collected in the supernatant and purified on Protein-A-agarose beads.
